Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2
Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…Rotigotine protects dopaminergic neurons by targeting serotonin 1A receptors on astrocytes
Objective: In this study, we examined neuroprotective effects of rotigotine and involvement of serotonin 1A (5-HT1A) receptors on astrocytes in neuroprotective action of the drug…Botulinum toxin injection for Pisa syndrome in Parkinson’s disease
Objective: We sought to assess the clinical efficacy of Botulinum toxin (BoNT) injection for Pisa syndrome (PS) using a combined Magnetic Resonance Imaging (MRI)-, Ultrasonography…Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone…Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
Objective: To evaluate the effect of Mate leaves extracts on the survival and maturation of dopaminergic neurons in vitro. Background: Parkinson's disease (PD) is caused…7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?
Objective: (i) To collect all the levodopa equivalent doses (LED) formulae and references used in clinical trials in Parkinson’s disease (PD) since the publication of…Comparison of low versus high frequency stimulation on stuttering in Parkinson’s disease patients with bilateral subthalamic nucleus deep brain stimulation
Objective: The objective of this study was to identify the prevalence of stuttering in PD patients with bilateral STN DBS compared to medically-treated PD (PD-MED)…Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations
Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial
Objective: Evaluate the safety of VY-AADC01, an AAV2 gene therapy vector with human aromatic L-amino acid decarboxylase (AADC) administered bilaterally to the putamen using intraoperative…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a novel once-daily…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 177
- Next Page »